Abstract:Breast cancer (BC) and hepatitis virus infections pose significant challenges to global public health. Since the mid-2000s, the incidence of BC among women has exhibited a consistent upward trajectory, with an annual average increase of 0.6%. This malignancy now accounts for 32% of all female cancer cases and has emerged as a leading cause of cancer-related mortality in women. [ 1 ] The World Health Organization reported that in 2019, viral hepatitis was responsible for 1.1 million deaths globally, with a staggering 96% attributed to hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. In the same year, the World Health Organization reported that 296 million people were living with chronic HBV infection and 58 million with chronic HCV infection, with each virus contributing to 1.5 million new infections annually. [ 2 ]

Female patients with hepatitis B may exhibit a reduced risk of breast cancer: A review of NHANES data